3,196 AbbVie Inc. $ABBV Shares Sold by Welch & Forbes LLC

Posted by Francis Steltz on Nov 10th, 2026

Welch & Forbes LLC lessened its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 342,782 shares of the company’s stock after selling 3,196 shares during the period. AbbVie comprises about 1.0% of Welch & Forbes LLC’s portfolio, making the stock its 27th biggest position. Welch & Forbes LLC’s holdings in AbbVie were worth $89,668,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in ABBV. State Street Corp increased its position in AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. Corient Private Wealth LP acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after purchasing an additional 106,091 shares during the period. Legal & General Group Plc bought a new stake in shares of AbbVie in the 2nd quarter valued at $2,905,952,000. Finally, Deutsche Bank AG boosted its stake in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after purchasing an additional 1,241,587 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ABBV. Citigroup upped their price target on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Scotiabank lifted their price objective on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and boosted their price objective for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. Piper Sandler boosted their price objective on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Finally, HSBC upped their target price on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $297.46.

Read Our Latest Analysis on AbbVie

AbbVie Price Performance

NYSE:ABBV opened at $292.87 on Tuesday. The business has a fifty day simple moving average of $272.71 and a two-hundred day simple moving average of $239.42. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $302.93. The company has a market capitalization of $517.69 billion, a P/E ratio of 50.41, a P/E/G ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The company had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.86 earnings per share. As a group, analysts anticipate that AbbVie Inc. will post 13.99 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be issued a $1.82 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is presently 119.10%.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.06% of the company’s stock.

AbbVie Company Profile

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas.

Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

AbbVie was established in 2013 as a spin-off from Abbott Laboratories and is headquartered in North Chicago, Illinois.